Search

Your search keyword '"Jiang, Zhenyu"' showing total 1,052 results
Start Over Author "Jiang, Zhenyu"
1,052 results on '"Jiang, Zhenyu"'

204. Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study

Author

Leng, Xiaomei, primary, Lin, Wei, additional, Liu, Shixue, additional, Kanik, Keith, additional, Wang, Cunshan, additional, Wan, Weiguo, additional, Jiang, Zhenyu, additional, Liu, Yi, additional, Liu, Shengyun, additional, Zhang, Zhuoli, additional, Zhang, Zhiyi, additional, Xu, Jian, additional, Tan, Wenfeng, additional, Hu, Jiankang, additional, Li, Jingyang, additional, Liu, Ju, additional, Gunay, Levent M., additional, Dina, Oluwaseyi, additional, Kinch, Cassandra, additional, and Zeng, Xiaofeng, additional

Published
2023
Full Text
View/download PDF

217. Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII

Author

Gui, Yinli, primary, Bai, Wei, additional, Xu, Jian, additional, Duan, Xinwang, additional, Zhan, Feng, additional, Zhao, Chen, additional, Jiang, Zhenyu, additional, Li, Zhijun, additional, Wu, Lijun, additional, Liu, Shengyun, additional, Yang, Min, additional, Wei, Wei, additional, Wang, Ziqian, additional, Zhao, Jiuliang, additional, Wang, Qian, additional, Leng, Xiaomei, additional, Tian, Xinping, additional, Li, Mengtao, additional, Zhao, Yan, additional, and Zeng, Xiaofeng, additional

Published
2022
Full Text
View/download PDF

218. Chinese registry of rheumatoid arthritis (CREDIT) V: sex impacts rheumatoid arthritis in Chinese patients

Author

Jiang, Nan, primary, Li, Qin, additional, Li, Hongbin, additional, Fang, Yongfei, additional, Wu, Lijun, additional, Duan, Xinwang, additional, Xu, Jian, additional, Zhao, Cheng, additional, Jiang, Zhenyu, additional, Wang, Yanhong, additional, Wang, Qian, additional, Leng, Xiaomei, additional, Li, Mengtao, additional, Tian, Xinping, additional, and Zeng, Xiaofeng, additional

Published
2022
Full Text
View/download PDF

232. Design and Verification of Attitude Control System for a Boost-Glide Rocket

Author

Shifeng Zhang, Fan Xiaoshuai, Jiang Zhenyu, Liu Longbin, and Xibin Bai

Subjects
Boost-glide, business.product_category, General Computer Science, Computer science, attitude control, PID, General Engineering, PID controller, ComputerApplications_COMPUTERSINOTHERSYSTEMS, Standard deviation, TK1-9971, Attitude control, hardware-in-the-loop simulation, Rocket, Control theory, Control system, Trajectory, General Materials Science, Electrical engineering. Electronics. Nuclear engineering, business, Engineering design process
Abstract

The boost-glide rocket needs to maneuver in the atmosphere with complex flight conditions, which is a big challenge for the attitude control system. In this paper, the design process of the control system is analyzed. With specific points of the flight trajectory, the design of an improved proportional-integrative-derivative (PID) controller based on the small perturbation theory is carried out. Design approach of the attitude control system is verified by the six-degree-freedom model simulation. The rocket flight control program is written to the onboard computer so that hardware-in-the-loop simulation experiment is completed. Experimental results show that the mean and standard deviation of the error between simulation value and experiment value are below 0.5°, so the control parameters and design method are reasonable with a great attitude tracking effect. This paper proposes the design and verification method of a boost-glide rocket attitude control system, which can provide a reference for design of the boost-glide rocket around the world.

Published
2021

233. Clinical value of the prognostic nutritional index and red blood cell distribution width‐to‐albumin ratio for the prediction of severity of and mortality associated with Stevens–Johnson syndrome/toxic epidermal necrolysis.

Author

Zhang, Zhibin, Yu, Kaihui, Jiang, Zhenyu, Liu, Ougen, Wan, Chuan, Wu, Hongxuan, and Cao, Xianwei

Abstract

The prognostic nutritional index (PNI) and red blood cell distribution width‐to‐albumin ratio (RAR) are considered to be related to the prognosis of disease severity. However, the role of these biomarkers in predicting Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) severity and mortality is unclear. The aim of the current study was to investigate the association of PNI and RAR with severity and mortality in individuals with SJS/TEN. Clinical data were retrospectively collected from 74 individuals with SJS/TEN and 74 healthy individuals, who were matched for age and sex during the same period. PNI, RAR, and other indicators were compared between individuals with SJS/TEN and healthy controls. The association of PNI and RAR with SJS/TEN severity was assessed using Spearman or Pearson correlation analyses. Individuals with SJS/TEN were categorized into two groups, either survivors or nonsurvivors. The correlation between PNI, RAR, and SJS/TEN mortality was analyzed using univariate and multivariate logistic regression. The predictive value of the previously mentioned indicators on the mortality of patients with SJS/TEN was assessed using receiver operating characteristic curve analysis. The RAR level of patients with SJS/TEN was greater than that of the control group (p < 0.05), whereas PNI was lower. In compliance with correlation analysis, RAR was positively correlated with SCORTEN (Score of Toxic Epidermal Necrolysis) and ABCD‐10 (age, bicarbonate, cancer, dialysis, 10% body surface area) (p < 0.05), and PNI was negatively correlated (p < 0.05). RAR is a risk factor for death in patients with SJS/TEN, but an elevated PNI level is a protective factor for mortality. The best cutoff values of PNI and RAR for predicting death in patients with SJS/TEN were 31.375 (sensitivity, 84.7%; specificity, 80%) and 0.486 (sensitivity, 73.3%; specificity, 84.7%). These results underscore the potential clinical value of PNI and RAR as appropriate and meaningful biomarkers to assess the severity of SJS/TEN and the mortality associated with it. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

246. Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study

Author

Ye, Hua, Liu, Shengyun, Xu, Jian, Chai, Kexia, He, Dongyi, Fang, Yongfei, Xie, Qibing, Liu, Huaxiang, Liu, Ying, Hua, Bingzhu, Hu, Jiankang, Zhang, Zhiyi, Zhou, Mingxuan, Zhao, Dongbao, Li, Yan, Jiang, Zhenyu, Wang, Meimei, Li, Jingyang, Zhang, Zhuoli, Li, Xiaomei, Li, Yang, Sun, Erwei, Bi, Liqi, Wei, Wei, Tie, Ning, He, Lan, Huang, Xiangyang, Zhang, Yan, Huang, Qingchun, Wang, Xiaofei, Liu, Xiangyuan, Li, Jing, and Su, Yin

Abstract

Objectives: The aim of this work is to verify the non-inferior efficacy and safety of CMAB008 compared with innovator infliximab in rheumatoid arthritis patients combined with methotrexate. Methods: We conducted a randomized, double-blinded, parallel, positive control design, multicenter study, with a stable dose of methotrexate. Patients were enrolled randomly with a ratio of 1:1 to receive intravenously CMAB008 3 mg/kg or innovator infliximab 3 mg/kg at weeks 0, 2, 6, 14, 22 and 30. The primary efficacy endpoint was American College of Rheumatology 20% improvement criteria (ACR20) response rate at week 30. The non-inferiority was established if the lower limit of the one-sided 97.5% confidence interval (CI) for the difference was more than − 15% and the equivalence was established if the two-sided 95% CI was within ± 15% in an exploratory equivalence analysis. The secondary endpoints included other efficacy assessment parameters, as well as immunogenicity, safety, and pharmacokinetics. Results: In the full analysis population (FAS), 110 (57.6%) of 191 patients in the CMAB008 group and 120 (62.2%) of 193 patients in the innovator infliximab group reached the primary outcome of ACR20 at week 30. The differences of the rates were − 4.6% and the lower limit of one-sided 97.5% confidence interval was − 14.29%, not less than the lower limit of the non-inferiority margin (− 15%); so CMAB008 was non-inferior to innovator infliximab. Further, CMAB008 was equivalent to innovator infliximab both in FAS (difference − 4.6%, 95% CI − 14.29% to 5.12%) and PPS (difference – 3.3%, 95% CI – 13.18% to 6.62%). The efficacy, safety, immunogenicity, and pharmacokinetics are highly similar between CMAB008 and innovator infliximab. Conclusions: Non-inferior efficacy of CMAB008 to innovator infliximab is illustrated with similar early and lasting therapeutic effects, and the equivalence is further demonstrated. CMAB008 is well tolerated and has semblable safety compared with the innovator infliximab. Trial registration number: NCT03478111.

Published
2023
Full Text
View/download PDF

247. Dynamic response of expanded polystyrene concrete during low speed impact

Author

Liu, Yiping, Ma, Dongpeng, Jiang, Zhenyu, Xiao, Fan, Huang, Xinxiong, Liu, Zejia, and Tang, Liqun

Subjects
Concrete -- Analysis -- Mechanical properties, Polystyrene -- Analysis -- Chemical properties, Business, Construction and materials industries
Abstract

ABSTRACT The impact response of lightweight concrete filled with expanded polystyrene beads (EPS concrete) has been studied experimentally using a drop hammer system equipped with a high speed photography system. [...]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results